ArticleNature communications2026
Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma.
Abstract read
In one paragraph
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
JuanFei Peng *Bridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
JiaJin Yang *Bridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Georgia Antonopoulou *Bridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID http://orcid.org/0000-0001-9681-4890
Rui FangBridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Bikash AdhikariInstitute of Biochemistry, University of Kiel, Kiel, Germany.ORCID http://orcid.org/0000-0002-9064-0356
Markus VogtInstitute of Biochemistry, University of Kiel, Kiel, Germany.ORCID http://orcid.org/0000-0002-4525-2901
Elmar WolfInstitute of Biochemistry, University of Kiel, Kiel, Germany.ORCID http://orcid.org/0000-0002-5299-6335
Chong SunDivision Immune Regulation in Cancer, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-9008-2158
Shangce DuDivision Immune Regulation in Cancer, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.
Laura GodfreyBridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Aayush GuptaDepartment of Internal Medicine II, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.
Marija Trajkovic-ArsicBridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Nicole TeichmannDepartment of Internal Medicine II, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.
Barbara T GrünwaldGerman Cancer Consortium (DKTK), partner site Essen, a partnership between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, Germany.
Niklas KrebsGerman Cancer Consortium (DKTK), partner site Essen, a partnership between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, Germany.
Katja SteigerInstitute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-7269-5433
Carolin MoglerInstitute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0003-3400-7254
Kristina AlthoffBridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Xin WangBridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Giovanni GiglioBridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID http://orcid.org/0009-0009-0349-3756
Sven-Thorsten LiffersBridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Konstantinos SavvatakisBridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Rickmer BrarenGerman Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-6039-6957
Rita T LawlorDepartment of Engineering for Innovation Medicine, University of Verona, Verona, Italy.ORCID http://orcid.org/0000-0003-3160-0634
Aldo ScarpaARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.ORCID http://orcid.org/0000-0003-1678-739X
Diana BehrensEPO - Experimental Pharmacology and Oncology GmbH, Berlin, Germany.
Karl S LangInstitute of Immunology, Medical Faculty, University of Duisburg-Essen, Essen, Germany.
Phyllis F CheungBridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. f.cheung@dkfz-heidelberg.de.ORCID http://orcid.org/0000-0002-0075-5679
Jens T SivekeBridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. j.siveke@dkfz.de.ORCID http://orcid.org/0000-0002-8772-4778
Funding
Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 01KD2206A/SATURN3Deutsche Forschungsgemeinschaft (German Research Foundation) 418179183Deutsche Forschungsgemeinschaft (German Research Foundation) 421166016Deutsche Forschungsgemeinschaft (German Research Foundation) 450917483Deutsche Krebshilfe (German Cancer Aid) 70115201Deutsches Krebsforschungszentrum (German Cancer Research Center) DKTKEC | Seventh Framework Programme (EC Seventh Framework Programm) 602783Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen (MIWF-NRW) CANcer TARgeting (CANTAR)
Abstract
GATA6 promotes epithelial phenotypes and limits epithelial-to-mesenchymal (EMT) transition in pancreatic ductal adenocarcinoma (PDAC). Here we show that GATA6 defines a tumor cell state that induces MHCI expression and anti-tumor cytotoxicity upon therapy. In human PDAC, GATA6 expression correlates with immune cell infiltration, and spatial analysis reveals interaction between GATA6
Indexed as
Carcinoma, Pancreatic DuctalGATA6 Transcription FactorPancreatic NeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorEpigenesis, GeneticEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHistone Deacetylase InhibitorsHumansMiceMice, Inbred C57BLProtein Kinase InhibitorsGATA6 protein, humanGATA6 Transcription FactorHistone Deacetylase InhibitorsProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.